Acute airway compromise after recombinant human TSH administration: A case report and review of the literature.
Acute Disease
Aged, 80 and over
Airway Obstruction
/ chemically induced
Carcinoma
/ therapy
Humans
Iodine Radioisotopes
Male
Medical Illustration
Radiofrequency Ablation
/ adverse effects
Recombinant Proteins
/ adverse effects
Thyroid Gland
/ drug effects
Thyroid Neoplasms
/ therapy
Thyrotropin
/ adverse effects
Thyroid cancer
airway
laryngoplasty
rhTSH
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
29
07
2019
revised:
07
10
2019
accepted:
08
11
2019
pubmed:
11
12
2019
medline:
1
1
2021
entrez:
11
12
2019
Statut:
ppublish
Résumé
Radioiodine ablation is a commonly utilized treatment for differentiated thyroid carcinoma. Uptake of radioiodine can be enhanced by pretreatment with thyroid hormone withdrawal or administration of recombinant human thyroid-stimulating hormone (rhTSH). rhTSH is generally well-tolerated with minimal adverse effects. However, in patients with extensive tumor burden in confined anatomic spaces, rapid enlargement of normal or neoplastic thyroid tissue secondary to rhTSH administration can result in significant compressive effects. In this report, we describe a case of rapid airway deterioration requiring intubation in a patient with involvement of the thyroid cartilage by papillary thyroid carcinoma. Laryngoscope, 122:0000-0000, 2019 Laryngoscope, 130:2725-2727, 2020.
Substances chimiques
Iodine Radioisotopes
0
Recombinant Proteins
0
Thyrotropin
9002-71-5
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2725-2727Informations de copyright
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Reiners C, Farahati J. 131I therapy of thyroid cancer patients. Q J Nucl Med 1999;43:324-335.
Schlumberger M, Pacini F. Thyroid Tumors. 5th ed. Paris, France: Editions Nucle'on; 2003: 3-317.
McDougall IR, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 2001;13:39-43.
Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994;78:188-196.
Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337: 888-896.
Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-3885.
Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999;84:3867-3871.
Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of the literature. Endocr Pract 2000;6:460-464.
Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001;86:5148-5151.
Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002;25:44-52.
Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid cancer: single-center study of 54 patients. Eur J Nucl Med Mol Imaging 2003;30:1077-1086.
Wolffenbuttel BH, Coppes MH, Bongaerts AH, Glaudemans AW, Links TP. Unexpected symptoms after rhTSH administration due to occult thyroid carcinoma metastasis. Neth J Med 2013;71:253-256.
Traboulsi H, El Natout T, Skaff G, Hamdan AL. Adverse reaction to hyaluronic acid injection laryngoplasty: a case report. J Voice. 2017;;31:245-e1-245-e2.
Shamanna SG, Bosch JD. Injection laryngoplasty: a serious reaction to hyaluronic acid. J Otolaryngol Head Neck Surg 2011;40:E39-E42.
Halderman AA, Bryson PC, Benninger MS, et al. Safety and length of benefit of restylane for office-based injection medialization-a retrospective review of one institution's experience. J Voice 2014;28:631-635.
Rudolf R, Sibylle B. Laryngoplasty with hyaluronic acid in patients with unilateral vocal fold paralysis. J Voice 2012;26:785-791.
Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:3637-3642.